{
    "data": [
        {
            "title": "Here's Why Dr. Reddy's Laboratories (NSE:DRREDDY) Has Caught The Eye Of Investors",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><p> It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making.  But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses.  A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up. </p><p> So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like <strong>Dr. Reddy's Laboratories</strong> (<a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/stocks/in/pharmaceuticals-biotech/nse-drreddy/dr-reddys-laboratories-shares\" rel=\"noopener noreferrer\" target=\"_blank\">NSE:DRREDDY</a>). While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation - especially if its growing. </p><p class=\"link-injector\"><a class=\"company-report-links\" data-vars-link-type=\"investing-ideas\" href=\"https://simplywall.st/discover/investing-ideas/434423/us-midstream-oil-and-gas-pipeline-operators/global\" rel=\"noopener noreferrer\" target=\"_blank\">Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2> How Quickly Is Dr. Reddy's Laboratories Increasing Earnings Per Share? </h2><p> The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually.  That means EPS growth is considered a real positive by most successful long-term investors.   It certainly is nice to see that Dr. Reddy's Laboratories has managed to grow EPS by 24% per year over three years.   If growth like this continues on into the future, then shareholders will have plenty to smile about.   </p><p> Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market.    While we note Dr. Reddy's Laboratories achieved similar EBIT margins to last year, revenue grew by a solid 14% to ₹342b.  That's a real positive.   </p><p> You can take a look at the company's revenue and earnings growth trend, in the chart below.  For finer detail, click on the image. </p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/in/pharmaceuticals-biotech/nse-drreddy/dr-reddys-laboratories-shares/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"earnings-and-revenue-history\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"1120\" loading=\"lazy\" src=\"https://images.simplywall.st/asset/chart/881725-earnings-and-revenue-history-1-dark-2/1761871494300\" width=\"1642\"/></a><figcaption class=\"wp-caption-text\">NSEI:DRREDDY Earnings and Revenue History October 31st 2025</figcaption></figure> <p><span class=\"veryHighlightLink\"><a class=\"company-report-links\" data-vars-link-type=\"cta\" href=\"https://simplywall.st/stocks/in/pharmaceuticals-biotech/nse-drreddy/dr-reddys-laboratories-shares\" rel=\"noopener noreferrer\" target=\"_blank\"> Check out our latest analysis for Dr. Reddy's Laboratories </a></span></p><p> The trick, as an investor, is to find companies that are <em>going to</em> perform well in the future, not just in the past. While crystal balls don't exist, you can check <a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/stocks/in/pharmaceuticals-biotech/nse-drreddy/dr-reddys-laboratories-shares/future\" rel=\"noopener noreferrer\" target=\"_blank\">our visualization of consensus analyst forecasts for Dr. Reddy's Laboratories' future EPS</a> 100% free.  </p><h2>Are Dr. Reddy's Laboratories Insiders Aligned With All Shareholders?</h2> <p> Owing to the size of Dr. Reddy's Laboratories, we wouldn't expect insiders to hold a significant proportion of the company.  But we do take comfort from the fact that they are investors in the company.     Indeed, they have a considerable amount of wealth invested in it, currently valued at ₹268b.   Coming in at 27% of the business, that holding gives insiders a lot of influence, and plenty of reason to generate value for shareholders.  So there is opportunity here to invest in a company whose management have tangible incentives to deliver.   </p> <h2> Does Dr. Reddy's Laboratories Deserve A Spot On Your Watchlist? </h2><p> You can't deny that Dr. Reddy's Laboratories has grown its earnings per share at a very impressive rate. That's attractive.   This EPS growth rate is something the company should be proud of, and so it's no surprise that insiders are holding on to a considerable chunk of shares.  On the balance of its merits, solid EPS growth and company insiders who are aligned with the shareholders would indicate a business that is worthy of further research.     You should always think about risks though. Case in point, we've spotted <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/in/pharmaceuticals-biotech/nse-drreddy/dr-reddys-laboratories-shares\" rel=\"noopener noreferrer\" target=\"_blank\"> <strong> 1 warning sign for Dr. Reddy's Laboratories</strong> </a> you should be aware of.   </p><p> Although Dr. Reddy's Laboratories certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/10228/fast-growing-stocks-with-high-insider-ownership\" rel=\"noopener noreferrer\" target=\"_blank\">handpicked selection of Indian companies that not only boast of strong growth but have strong insider backing</a>. </p><p><em>Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.</em></p></div>",
            "pub_date": "2025-10-31 08:46:48",
            "link": "https://simplywall.st/stocks/in/pharmaceuticals-biotech/nse-drreddy/dr-reddys-laboratories-shares/news/heres-why-dr-reddys-laboratories-nsedrreddy-has-caught-the-e",
            "image": "https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Zimmer Biomet (ZBH): Evaluating Current Valuation After Recent Modest Share Price Gains",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\">Zimmer Biomet Holdings (ZBH) has caught the attention of investors after modest share price moves over the month, up about 1%. The company’s performance trends provide investors with several factors to consider.\n<p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Zimmer Biomet Holdings.</a></p> <p>Zimmer Biomet’s latest share price movements reflect a moderate uptick this month. Looking at a broader timeframe shows a mixed picture, with momentum building over the last quarter, yet a 1-year total shareholder return of -6% and a five-year total return down more than 23%. Short-term recovery is apparent, but a longer-term turnaround remains a work in progress.</p> <p>If the recent run has you thinking about fresh ideas in medtech, take the next step and explore <a class=\"company-report-links\" data-vars-link-type=\"cta_healthcare_screener\" href=\"https://simplywall.st/discover/investing-ideas/7008/healthcare-sector/global\" rel=\"noopener noreferrer\" target=\"_blank\">See the full list for free.</a></p> <p>This raises a key question for investors: is Zimmer Biomet currently trading below its true potential, or are future gains already reflected in the share price, leaving little room for upside?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Most Popular Narrative: 10.2% Undervalued</h2> <p>Following a last close at $99.56, the most widely followed narrative assigns Zimmer Biomet a fair value at $110.92, indicating further upside from here. This collective view brings together analyst assumptions about revenue, margin improvement, and future profit multiples to derive today's perceived opportunity.</p> <blockquote> <p><em>The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings. This enables margin expansion due to product mix and drives recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/wztul17o-aging-population-and-robotics-will-elevate-orthopedic-care-cq7j\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Curious what catalysts push this valuation higher? Explore the narrative's bold assumptions about margin expansion and lasting demand for surgical robotics. The numbers behind this story might surprise you. Find out which future growth levers analysts are betting on to justify the premium placed on Zimmer Biomet’s potential.</p> <p><strong>Result: Fair Value of $110.92 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/wztul17o-aging-population-and-robotics-will-elevate-orthopedic-care-cq7j\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, persistent pricing pressures or delays in key robotic launches could quickly change the outlook and put pressure on future returns for Zimmer Biomet.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Zimmer Biomet Holdings narrative.</a></p> <h2> Build Your Own Zimmer Biomet Holdings Narrative</h2> <p>If you see things differently or want to dig into the details yourself, you can shape your own perspective on Zimmer Biomet in just a few minutes. <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative\" href=\"https://support.simplywall.st/hc/en-us/articles/10353275550479-Stock-Valuator-with-Narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Do it your way</a></p> <p>A great starting point for your Zimmer Biomet Holdings research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a> that could impact your investment decision.</p> <h2>Looking for More Investing Opportunities?</h2> <p>Smart investors never settle for just one stock idea, especially when markets are always evolving. Stay ahead by targeting trends that others might miss.</p> <ul> <li>Lock in reliable income streams by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/146/dividend-powerhouses-3-yield/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 24 dividend stocks with yields &gt; 3%</a>, which features strong dividend deals and yields that can bolster your portfolio’s resilience.</li> <li>Catalyze your portfolio’s growth with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_ai_stocks\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 26 AI penny stocks</a>, revealing companies at the forefront of breakthrough artificial intelligence innovations.</li> <li>Tap into tomorrow’s technological breakthroughs by finding standouts among <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_quantum\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 28 quantum computing stocks</a>, as these companies are pushing the boundaries in quantum computing applications.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:46:47",
            "link": "https://simplywall.st/stocks/us/healthcare/nyse-zbh/zimmer-biomet-holdings/news/zimmer-biomet-zbh-evaluating-current-valuation-after-recent",
            "image": "https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "SEACOR Marine Holdings (SMHI) Losses Worsen, Undermining Hopes for Profitability Turnaround",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><p>SEACOR Marine Holdings (SMHI) is currently unprofitable, with losses increasing over the past five years at a compound annual rate of 3.6%. Over the last year, the company’s profitability has not improved, and investors should note there is no concrete evidence of high-quality past earnings in the current results. With no reward factors identified in the latest data, the continued trend of mounting losses and lack of growth momentum highlights why risks remain at the forefront for anyone tracking the stock this earnings season.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/us/energy/nyse-smhi/seacor-marine-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for SEACOR Marine Holdings.</a> <p>Now, let’s see how these headline results hold up against the wider market narratives. In the next section, we will line up the numbers with the stories analysts and the community are following.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/energy/nyse-smhi/seacor-marine-holdings/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:SMHI Earnings &amp; Revenue History as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/9da4329e-cbe7-4730-9d15-69e0fdce7594/chart/earnings-and-revenue-history\" width=\"746\"/></a><figcaption>NYSE:SMHI Earnings &amp; Revenue History as at Oct 2025</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Price-to-Sales Multiple Below Industry, But Above Peers</h2> <ul> <li>SEACOR Marine trades at a Price-to-Sales (P/S) ratio of 0.7x, which is lower than the US Energy Services industry average of 1x and above the peer average of 0.5x. This highlights how investors are pricing in both sector-wide headwinds and company-specific concerns relative to direct competitors.</li> <li>This supports the view that ongoing sector stress and company risks are being partially balanced by potential for improved contract visibility.\n    <ul> <li>The industry discount reflects bears’ focus on lack of profitability and growth, while the premium to peers supports those watching for operational resilience or market recovery tailwinds.</li> <li>Bears continue to cite stagnant profitability and the company’s financial position as reasons for trading below broader sector multiples, while the ratio implies some hope that conditions could shift favorably if effective fleet or contract moves materialize.</li> </ul> </li> </ul> <h2>No Evidence of Growth or High-Quality Earnings</h2> <ul> <li>There is not sufficient data to assess SEACOR Marine’s expected revenue or earnings growth, and filings offer no evidence of high-quality past earnings. This leaves little for bulls to point to as an upside driver at this time.</li> <li>Bears highlight the absence of growth catalysts and the company’s inability to demonstrate sustained profitability.\n    <ul> <li>Unlike some industry peers showing clear revenue growth or forecast visibility, SEACOR Marine’s filings suggest that both top-line and bottom-line momentum are lacking.</li> <li>This ongoing growth gap underlines the bearish view that the company’s current trajectory fails to convince markets of any near-term turnaround, intensified by the lack of reward factors in the data.</li> </ul> </li> </ul> <h2>Financial Position Limits Upside Potential</h2> <ul> <li>SEACOR Marine is not regarded as being in a strong financial position, with continued unprofitability and no evidence of improved profitability over the last year. This makes it especially vulnerable to sector swings.</li> <li>Bears argue that risks around financial stability will persist unless the company can show tangible steps towards breaking the loss trend.\n    <ul> <li>With revenue and earnings not expected to grow, the justification for an improved valuation or sustained share price remains weak compared to steady or recovering peers.</li> <li>The company’s discounted P/S ratio, while partially reflecting sector caution, increases investor sensitivity to any setback in operational performance or industry outlook.</li> </ul> </li> </ul> <h2> Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on SEACOR Marine Holdings's <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://www.simplywall.st/stocks/us/energy/nyse-smhi/seacor-marine-holdings/past\" rel=\"noopener noreferrer\" target=\"_blank\">growth</a> and its <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://www.simplywall.st/stocks/us/energy/nyse-smhi/seacor-marine-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">valuation</a> to see if today's price is a bargain. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://simplywall.st/portfolio/demo\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> now so you don't miss the next big move.</p> <h2>See What Else Is Out There</h2> <p>SEACOR Marine’s persistent losses, lack of growth momentum, and ongoing financial vulnerability leave investors exposed to further downside if conditions worsen.</p> <p>Want companies that can weather uncertainty? Use <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/global\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (1984 results)</a> to focus on businesses with stronger financial footing and resilience against the ups and downs SEACOR currently faces.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:46:45",
            "link": "https://simplywall.st/stocks/us/energy/nyse-smhi/seacor-marine-holdings/news/seacor-marine-holdings-smhi-losses-worsen-undermining-hopes",
            "image": "https://images.simplywall.st/asset/industry/1022000-choice2-main-header/1585186558401",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Hawthorn Bank (HWBK) Margin Surge Reinforces Bullish Profitability Narratives",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><p>Hawthorn Bancshares (HWBK) reported net profit margins of 27.5%, a sharp improvement compared to 7.5% a year ago. EPS surged 389.3% over the past twelve months. This turnaround stands in contrast to the company’s five-year average, which saw earnings decline by 11% per year. Shares trade at a Price-to-Earnings Ratio of 10.2x, lower than both peer and industry averages. This signals an attractive valuation relative to US bank stocks. The company’s management is also recognized for delivering high quality earnings as profitability rebounds.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/us/banks/nasdaq-hwbk/hawthorn-bancshares\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for Hawthorn Bancshares.</a> <p>The next section puts these headline numbers side by side with the dominant narratives shaping investor expectations, examining which stories are confirmed and which might require updating.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/banks/nasdaq-hwbk/hawthorn-bancshares/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:HWBK Earnings &amp; Revenue History as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/1167c1ff-5770-4011-aafd-90fe5abe456c/chart/earnings-and-revenue-history\" width=\"746\"/></a><figcaption>NasdaqGS:HWBK Earnings &amp; Revenue History as at Oct 2025</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Margin Expansion Lifts Profit Quality</h2> <ul> <li>Net profit margin jumped to 27.5% from 7.5% last year, marking a clear shift in how efficiently the company turns revenue into profit.</li> <li>With profitability now well above recent history, prevailing market analysis highlights Hawthorn Bancshares' ability to buck its five-year trend of 11% average annual earnings decline and restore operating momentum.\n    <ul> <li>This margin improvement is seen as evidence that management has regained control over costs, supporting a narrative of “defensive stability” in volatile market conditions.</li> <li>However, the noticeable contrast with the multi-year average keeps investors watching for cues on whether this rebound can be consistently repeated or if it is a short-term spike.</li> </ul> </li> </ul> <h2>Dividend Attractiveness in Focus</h2> <ul> <li>EDGAR data spotlights the company’s dividend as a distinguishing feature, with income-focused investors likely to find comfort amid sector uncertainty even as broader growth remains in question.</li> <li>Hawthorn Bancshares stands out in the prevailing market view for offering a steady dividend at a time when peers are under earnings pressure.\n    <ul> <li>Reliable payout streams have historically attracted risk-averse buyers, and with profit margins surging, the company is positioned to maintain these distributions even as growth moderates.</li> <li>Still, the lack of signals about further dividend increases or rapid expansion keeps expectations for reward measured but stable.</li> </ul> </li> </ul> <h2>Valuation Discounts Against Peers</h2> <ul> <li>Shares currently trade at a Price-to-Earnings Ratio of 10.2x, which is below both the peer average of 11.4x and the broader US banks industry at 11x. This highlights a valuation discount that may appeal to bargain-seeking investors.</li> <li>Prevailing market view suggests this lower valuation multiple is a magnet for value portfolios, as Hawthorn Bancshares is not only less expensive than the average US bank but comes with profit margins that have recently strengthened.\n    <ul> <li>Value-focused investors are drawn to the combination of lower price multiples and improving profitability, seeing both as potential drivers of future returns.</li> <li>Yet, the company’s five-year history of earnings declines reminds investors that short-term valuation advantages may need sustained financial momentum to translate into outperformance.</li> </ul> </li> </ul> <h2> Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Hawthorn Bancshares's <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://www.simplywall.st/stocks/us/banks/nasdaq-hwbk/hawthorn-bancshares/past\" rel=\"noopener noreferrer\" target=\"_blank\">growth</a> and its <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://www.simplywall.st/stocks/us/banks/nasdaq-hwbk/hawthorn-bancshares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">valuation</a> to see if today's price is a bargain. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://simplywall.st/portfolio/demo\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> now so you don't miss the next big move.</p> <h2>See What Else Is Out There</h2> <p>Despite improved margins, Hawthorn Bancshares' longer-term record of declining earnings leaves uncertainty about the consistency and durability of its recent rebound.</p> <p>If you want more reliable growth from your investments, use <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_stable_growth\" href=\"https://simplywall.st/discover/investing-ideas/372939/stable-growth-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">stable growth stocks screener (2113 results)</a> to find companies showing a strong track record of steady performance across changing markets.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:46:45",
            "link": "https://simplywall.st/stocks/us/banks/nasdaq-hwbk/hawthorn-bancshares/news/hawthorn-bank-hwbk-margin-surge-reinforces-bullish-profitabi",
            "image": "https://images.simplywall.st/asset/industry/7013000-choice1-main-header/1585186561056",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "SK hynix (KRX:000660) Knows How To Allocate Capital Effectively",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><p> If you're looking for a multi-bagger, there's a few things to keep an eye out for.  Firstly, we'll want to see a proven <em>return</em> on capital employed (ROCE) that is increasing, and secondly, an expanding <em>base</em> of capital employed.  Put simply, these types of businesses are compounding machines, meaning they are continually reinvesting their earnings at ever-higher rates of return.    So when we looked at the ROCE trend of <strong>SK hynix</strong> (<a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/stocks/kr/semiconductors/kose-a000660/sk-hynix-shares\" rel=\"noopener noreferrer\" target=\"_blank\">KRX:000660</a>) we really liked what we saw.    </p><p class=\"link-injector\"><a class=\"company-report-links\" data-vars-link-type=\"investing-ideas\" href=\"https://simplywall.st/discover/investing-ideas/434616/us-dividend-powerhouses-with-a-forecast-yield-of-6percent/global\" rel=\"noopener noreferrer\" target=\"_blank\">We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</a></p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2> Understanding Return On Capital Employed (ROCE) </h2><p> If you haven't worked with ROCE before, it measures the 'return' (pre-tax profit) a company generates from capital employed in its business.  Analysts use this formula to calculate it for SK hynix: </p><p> <strong>Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)</strong> </p><p>0.31 = ₩32t ÷ (₩129t - ₩25t) <em>(Based on the trailing twelve months to June 2025)</em>.</p><p> So, <strong>SK hynix has an ROCE of 31%. </strong> That's a fantastic return and not only that, it outpaces the average of 7.5% earned by companies in a similar industry.   </p><p><span class=\"veryHighlightLink\"><a class=\"company-report-links\" data-vars-link-type=\"cta\" href=\"https://simplywall.st/stocks/kr/semiconductors/kose-a000660/sk-hynix-shares\" rel=\"noopener noreferrer\" target=\"_blank\"> Check out our latest analysis for SK hynix </a></span></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/kr/semiconductors/kose-a000660/sk-hynix-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"roce\" class=\"sc-8e1a88f-1 fOFOtB\" height=\"632\" loading=\"lazy\" src=\"https://images.simplywall.st/asset/chart/883357-roce-1-dark-2/1761871556004\" width=\"666\"/></a><figcaption class=\"wp-caption-text\">KOSE:A000660 Return on Capital Employed October 31st 2025</figcaption></figure><p> In the above chart we have measured SK hynix's prior ROCE against its prior performance, but the future is arguably more important.  If you'd like, you can  <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/kr/semiconductors/kose-a000660/sk-hynix-shares/future\" rel=\"noopener noreferrer\" target=\"_blank\">check out the forecasts from the analysts covering SK hynix </a> for <strong>free.</strong> </p><h2> The Trend Of ROCE </h2><p> Investors would be pleased with what's happening at SK hynix.   The data shows that returns on capital have increased substantially over the last  five years to 31%.  The amount of capital employed has increased too, by 74%.  So we're very much inspired by what we're seeing at SK hynix thanks to its ability to profitably reinvest capital.   </p><h2> The Bottom Line On SK hynix's ROCE </h2><p> To sum it up, SK hynix has proven it can reinvest in the business and generate higher returns on that capital employed, which is terrific.       And a remarkable 601% total return over the last  five years tells us that investors are expecting more good things to come in the future.   In light of that, we think it's worth looking further into this stock because if SK hynix can keep these trends up, it could have a bright future ahead.   </p><p> One more thing to note, we've identified <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/stocks/kr/semiconductors/kose-a000660/sk-hynix-shares\" rel=\"noopener noreferrer\" target=\"_blank\"> <strong> 1 warning sign </strong> with SK hynix </a>and understanding this should be part of your investment process.   </p><p> If you want to search for more stocks that have been earning high returns, check out this <strong>free</strong> <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/global\" rel=\"noopener noreferrer\" target=\"_blank\">list of stocks with solid balance sheets that are also earning high returns on equity.</a> </p></div>",
            "pub_date": "2025-10-31 08:46:44",
            "link": "https://simplywall.st/stocks/kr/semiconductors/kose-a000660/sk-hynix-shares/news/sk-hynix-krx000660-knows-how-to-allocate-capital-effectively",
            "image": "https://images.simplywall.st/asset/industry/8212000-choice1-main-header/1585186704996",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Daiichi Sankyo (TSE:4568) Surges on Breakthrough Oncology Data and Multiple New Drug Approvals",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><ul> <li>Between October 17 and October 29, 2025, Daiichi Sankyo and its partners announced a series of positive clinical trial results, including new regulatory approvals and strong efficacy and safety data for key oncology drugs such as ENHERTU, DATROWAY, DS-3939, and raludotatug deruxtecan across multiple cancer types.</li> <li>These recent updates highlight Daiichi Sankyo's expanding leadership in antibody-drug conjugate therapies and its progress in bringing innovative targeted cancer treatments to global markets.</li> <li>We’ll examine how new breast cancer trial approvals and notable data for ENHERTU and DATROWAY reshape the company’s investment narrative.</li> </ul><p>Find <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/us\" rel=\"noopener noreferrer\" target=\"_blank\">companies with promising cash flow potential yet trading below their fair value</a>.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Daiichi Sankyo Company Investment Narrative Recap</h2><p>To be a shareholder in Daiichi Sankyo, you need confidence in the company's ability to consistently deliver breakthrough oncology treatments while actively managing the risk that revenue is concentrated in a small number of blockbuster drugs. The recent slate of positive clinical results for ENHERTU, DATROWAY, and others reinforces Daiichi Sankyo's near-term catalyst, expanding approvals and broader uptake for its flagship antibody-drug conjugates, but does not materially resolve the company’s central risk of revenue concentration and competitive threats.</p> <p>One relevant announcement is Health Canada's regulatory approval of ENHERTU for new breast cancer indications, based on strong data from the DESTINY-Breast06 trial. This milestone aligns directly with investor hopes for faster market expansion and acts as a testament to pipeline execution, supporting the company’s narrative of strong growth prospects from its leading ADC portfolio.</p> <p>Yet, despite clinical momentum, investors should weigh the very real risk that...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/jp/pharmaceuticals-biotech/tse-4568/daiichi-sankyo-shares/l9lsqsvm-analysts-lower-daiichi-sankyo-price-target-as-new-cancer-data-drives-valuation-tweaks\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Daiichi Sankyo Company (it's free!)</a></p><p>Daiichi Sankyo Company's outlook anticipates ¥2,659.1 billion in revenue and ¥447.9 billion in earnings by 2028. This is based on an expected annual revenue growth rate of 11.4% and an increase in earnings of about ¥152 billion from the current ¥295.9 billion.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/jp/pharmaceuticals-biotech/tse-4568/daiichi-sankyo-shares/l9lsqsvm-analysts-lower-daiichi-sankyo-price-target-as-new-cancer-data-drives-valuation-tweaks\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Daiichi Sankyo Company's forecasts yield a ¥5517 fair value</a>, a 44% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4568/daiichi-sankyo-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSE:4568 Community Fair Values as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/3da34022-ad84-492d-b476-e9d83a1ae4e6/chart/community-fair-value\" width=\"746\"/></a><figcaption>TSE:4568 Community Fair Values as at Oct 2025</figcaption></figure> <p>Two Simply Wall St Community members place Daiichi Sankyo's fair value between ¥5,517 and ¥6,296. With recent clinical wins highlighting revenue concentration, broader market and policy risks remain front of mind for many.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/jp/pharmaceuticals-biotech/tse-4568/daiichi-sankyo-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 2 other fair value estimates on Daiichi Sankyo Company</a> - why the stock might be worth as much as 64% more than the current price!</p><h2>Build Your Own Daiichi Sankyo Company Narrative</h2><p>Disagree with existing narratives? <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://support.simplywall.st/hc/en-us/articles/10353275550479-Stock-Valuator-with-Narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Create your own in under 3 minutes</a> - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Daiichi Sankyo Company research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4568/daiichi-sankyo-shares\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4568/daiichi-sankyo-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Daiichi Sankyo Company research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Daiichi Sankyo Company's overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>We've found <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434616/us-dividend-powerhouses-with-a-forecast-yield-of-6percent/global\" rel=\"noopener noreferrer\" target=\"_blank\">21 US stocks that are forecast to pay a dividend yield of over 6% next year</a>. See the full list for free.</li><li>The end of cancer? These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434428/ai-diagnosis/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 emerging AI stocks are developing tech that will allow early identification of life changing diseases</a> like cancer and Alzheimer's.</li><li>Outshine the giants: these <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">26 early-stage AI stocks could fund your retirement</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:40:43",
            "link": "https://simplywall.st/stocks/jp/pharmaceuticals-biotech/tse-4568/daiichi-sankyo-shares/news/daiichi-sankyo-tse4568-surges-on-breakthrough-oncology-data",
            "image": "https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Duxton Farms Executive Chairman Acquires 3.3% More Stock",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><p> Potential <strong>Duxton Farms Limited</strong> (<a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/stocks/au/food-beverage-tobacco/asx-dbf/duxton-farms-shares\" rel=\"noopener noreferrer\" target=\"_blank\">ASX:DBF</a>) shareholders may wish to note that the Executive Chairman, Edouard Peter, recently bought AU$352k worth of stock, paying AU$0.97 for each share.    Although the purchase only increased their holding by 3.3%, it is still a solid purchase in our view.    </p> <p class=\"link-injector\"><a class=\"company-report-links\" data-vars-link-type=\"investing-ideas\" href=\"https://simplywall.st/discover/investing-ideas/434423/us-midstream-oil-and-gas-pipeline-operators/global\" rel=\"noopener noreferrer\" target=\"_blank\">Trump has pledged to \"unleash\" American oil and gas and these 15 US stocks have developments that are poised to benefit.</a></p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2> Duxton Farms Insider Transactions Over The Last Year </h2> <p> The insider Richard Magides made the biggest insider purchase in the last 12 months. That single transaction was for AU$1.5m worth of shares at a price of AU$1.17 each.    That means that an insider was happy to buy shares at above the current price of AU$0.86.  It's very possible they regret the purchase, but it's more likely they are bullish about the company.  We always take careful note of the price insiders pay when purchasing shares.   As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.     </p> <p> While Duxton Farms insiders bought shares during the last year, they didn't sell.    You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below.  If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date! </p><p><span class=\"veryHighlightLink\"><a class=\"company-report-links\" data-vars-link-type=\"cta\" href=\"https://simplywall.st/stocks/au/food-beverage-tobacco/asx-dbf/duxton-farms-shares\" rel=\"noopener noreferrer\" target=\"_blank\"> View our latest analysis for Duxton Farms </a></span></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/au/food-beverage-tobacco/asx-dbf/duxton-farms-shares/ownership\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"insider-trading-volume\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"872\" loading=\"lazy\" src=\"https://images.simplywall.st/asset/chart/545002494-insider-trading-volume-1-dark-2/1761856408773\" width=\"1642\"/></a><figcaption class=\"wp-caption-text\">ASX:DBF Insider Trading Volume October 30th 2025</figcaption></figure><p> Duxton Farms is not the only stock that insiders are buying. For those who like to find <strong>small cap companies at attractive valuations, </strong> this <strong>free</strong> <a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/discover/investing-ideas/16951/undervalued-small-caps-with-insider-buying\" rel=\"noopener noreferrer\" target=\"_blank\">list of growing companies with recent insider purchasing, could be just the ticket.</a> </p> <h2> Does Duxton Farms Boast High Insider Ownership? </h2><p> For a common shareholder, it is worth checking how many shares are held by company insiders.  I reckon it's a good sign if insiders own a significant number of shares in the company.   It appears that Duxton Farms insiders own 34% of the company, worth about AU$13m.  We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.  </p><h2> What Might The Insider Transactions At Duxton Farms Tell Us? </h2><p> The recent insider purchases are heartening.    We also take confidence from the longer term picture of insider transactions.   But on the other hand, the company made a loss during the last year, which makes us a little cautious.    When combined with notable insider ownership, these factors suggest Duxton Farms insiders are well aligned, and that they may think the share price is too low.      While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision.     To that end, you should learn about the <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/food-beverage-tobacco/asx-dbf/duxton-farms-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>3 warning signs </strong>we've spotted with Duxton Farms (including 2 which don't sit too well with us)</a>. </p><p> Of course <strong>Duxton Farms may not be the best stock to buy</strong>. So you may wish to see this <strong>free</strong> <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/16053/high-return-on-equity-low-debt\" rel=\"noopener noreferrer\" target=\"_blank\">collection of high quality companies.</a> </p><p><em>For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.</em></p></div>",
            "pub_date": "2025-10-31 08:40:43",
            "link": "https://simplywall.st/stocks/au/food-beverage-tobacco/asx-dbf/duxton-farms-shares/news/duxton-farms-executive-chairman-acquires-33-more-stock",
            "image": "https://images.simplywall.st/asset/industry/5121000-choice2-main-header/1585186862101",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "How Amneal Pharmaceuticals’ (AMRX) Return to Profitability and Respiratory Product Wins Have Changed Its Investment Story",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><ul> <li>Amneal Pharmaceuticals, Inc. reported strong third-quarter 2025 results, returning to profitability with US$784.51 million in sales and launching new products, including Brekiya® autoinjector for migraines and cluster headaches, while also receiving tentative FDA approval for its first metered-dose inhaler targeting asthma.</li> <li>These developments mark significant milestones in Amneal's expansion into complex respiratory and specialty therapies, reflecting a broadened pipeline and strengthening its position in underserved markets.</li> <li>We'll examine how Amneal's improved profitability and new respiratory product approval may influence its investment narrative going forward.</li> </ul><p>Explore <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">28 top quantum computing companies</a> leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Amneal Pharmaceuticals Investment Narrative Recap</h2><p>To own Amneal Pharmaceuticals, I think an investor needs to believe that continued expansion into complex generics and specialty products will offset persistent price pressure in U.S. generics and help diversify revenue streams. The company’s strong third-quarter results, return to profitability, and launch of new specialty products may strengthen the short-term investment case, but the primary risk of margin compression from intense generic market competition remains material and unchanged in light of this news.</p> <p>The recent tentative FDA approval for Amneal’s first metered-dose inhaler, a generic QVAR alternative for asthma, is highly relevant. This important milestone moves Amneal into the respiratory space and directly addresses the need for diversified growth catalysts beyond its established core portfolio, potentially aiding future margin resilience if successfully commercialized.</p> <p>However, despite financial improvements, investors should also know that heavy reliance on U.S.-based revenues means...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/3tt90axt-global-health-trends-and-pipeline-launches-will-fuel-future-potential-7800\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Amneal Pharmaceuticals (it's free!)</a></p><p>Amneal Pharmaceuticals' narrative projects $3.5 billion in revenue and $207.9 million in earnings by 2028. This requires 7.2% yearly revenue growth and a $204.5 million increase in earnings from the current $3.4 million.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/3tt90axt-global-health-trends-and-pipeline-launches-will-fuel-future-potential-7800\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Amneal Pharmaceuticals' forecasts yield a $12.67 fair value</a>, a 21% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"AMRX Community Fair Values as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/community-fair-value\" width=\"746\"/></a><figcaption>AMRX Community Fair Values as at Oct 2025</figcaption></figure> <p>Simply Wall St Community members estimate fair value for Amneal stock from US$11.94 to US$64.09, based on three distinct forecasts. You see the widest optimism alongside real concerns about margin pressure as competition intensifies in the generics space, inviting you to compare a spectrum of viewpoints.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Amneal Pharmaceuticals</a> - why the stock might be worth just $11.94!</p><h2>Build Your Own Amneal Pharmaceuticals Narrative</h2><p>Disagree with existing narratives? <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://support.simplywall.st/hc/en-us/articles/10353275550479-Stock-Valuator-with-Narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Create your own in under 3 minutes</a> - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Amneal Pharmaceuticals research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Amneal Pharmaceuticals research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amneal Pharmaceuticals' overall financial health at a glance.</li></ul><h2>Curious About Other Options?</h2><p>Our daily scans reveal stocks with breakout potential. Don't miss this chance:</p><ul><li>Rare earth metals are the new gold rush. Find out which <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">35 stocks are leading the charge</a>.</li><li>The end of cancer? These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434428/ai-diagnosis/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 emerging AI stocks are developing tech that will allow early identification of life changing diseases</a> like cancer and Alzheimer's.</li><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/us\" rel=\"noopener noreferrer\" target=\"_blank\">companies with promising cash flow potential yet trading below their fair value</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:40:43",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/news/how-amneal-pharmaceuticals-amrx-return-to-profitability-and",
            "image": "https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look at Japan Tobacco (TSE:2914) Valuation After Dividend Hike and New Earnings Forecasts",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><p>Japan Tobacco (TSE:2914) sent a clear signal to shareholders by raising its year-end dividend guidance and laying out fresh earnings forecasts for 2025. The updated dividend, now set at JPY 130 per share, exceeds previous expectations and was announced together with the company’s revenue and profit targets for the coming year.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/jp/food-beverage-tobacco/tse-2914/japan-tobacco-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Japan Tobacco.</a></p> <p>The upbeat dividend news and fresh forecasts came as Japan Tobacco’s momentum continues to build. Its share price has climbed 21.63% year-to-date. Over the past year, total shareholder return has reached 20.74%. The three- and five-year total returns are 108% and 221% respectively, underscoring the company’s resilience and robust recovery.</p> <p>If you’re feeling inspired by Japan Tobacco’s recent performance, it’s a great opportunity to cast a wider net and discover <a class=\"company-report-links\" data-vars-link-type=\"cta_fast_growing_high_insider_ownership_screener\" href=\"https://simplywall.st/discover/investing-ideas/10228/fast-growing-stocks-with-high-insider-ownership/global\" rel=\"noopener noreferrer\" target=\"_blank\">fast growing stocks with high insider ownership</a></p> <p>With Japan Tobacco’s stock posting impressive multi-year returns and upbeat guidance now public, the key question for investors is whether all the good news is already reflected in the price or if there is still a genuine buying opportunity.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Most Popular Narrative: 1% Undervalued</h2> <p>The current narrative sets Japan Tobacco’s fair value at ¥4,974, nearly identical to its last closing price of ¥4,925. This suggests the market is in line with consensus expectations. This close alignment puts the spotlight squarely on the assumptions and projections that are driving analysts’ confidence in their target.</p> <blockquote> <p><em>\"Analysts assume that profit margins will increase from 5.9% today to 17.0% in 3 years time. Analysts expect earnings to reach ¥645.1 billion (and earnings per share of ¥367.81) by about September 2028, up from ¥194.0 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting ¥710.6 billion in earnings, and the most bearish expecting ¥524.0 billion.\"</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/pp7ipaaf-reduced-risk-offerings-and-international-markets-will-secure-long-term-success-hbvz\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Can margins really triple in just a few short years? Behind this call are some daring profit forecasts and a debate among analysts that may surprise you. The full narrative reveals which numbers drive the remarkably precise fair value, as well as what is fueling all the disagreement.</p> <p><strong>Result: Fair Value of ¥4,974 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/pp7ipaaf-reduced-risk-offerings-and-international-markets-will-secure-long-term-success-hbvz\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, heavy reliance on Japan’s shrinking tobacco market and delayed profitability in reduced-risk products could quickly challenge the optimistic outlook.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/jp/food-beverage-tobacco/tse-2914/japan-tobacco-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Japan Tobacco narrative.</a></p> <h2>Another View: Market Multiples Paint a Different Picture</h2> <p>Looking through a price-to-earnings lens, Japan Tobacco trades at 45.1x, which is significantly higher than both its peer average (31.4x) and the broader Asian Tobacco industry (15x). Even when compared to the fair ratio of 39.4x, the current multiple suggests that investors are paying a notable premium for growth and stability that is not guaranteed.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/jp/food-beverage-tobacco/tse-2914/japan-tobacco-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price — find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/food-beverage-tobacco/tse-2914/japan-tobacco-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSE:2914 PE Ratio as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/e0b7d1cd-3d3e-4ab7-b7ba-db694685127b/chart/pe-multiple-vs-industry\" width=\"746\"/></a><figcaption>TSE:2914 PE Ratio as at Oct 2025</figcaption></figure><p> </p><h2> Build Your Own Japan Tobacco Narrative</h2> <p>If the numbers or assumptions above do not quite match your view, why not dig into the data and craft your own narrative in just a few minutes? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative\" href=\"https://support.simplywall.st/hc/en-us/articles/10353275550479-Stock-Valuator-with-Narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Do it your way</a></p> <p>A great starting point for your Japan Tobacco research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/jp/food-beverage-tobacco/tse-2914/japan-tobacco-shares\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 2 important warning signs</a> that could impact your investment decision.</p> <h2>Looking for More Investment Ideas?</h2> <p>Smart investors do not limit themselves to just one opportunity. Expand your horizons and uncover companies redefining their industries with the help of our hand-picked screeners below.</p> <ul> <li>Supercharge your portfolio by targeting companies offering robust cash flow potential with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 856 undervalued stocks based on cash flows</a> that others may be overlooking.</li> <li>Tap into the explosive rise of machine learning and automation by using <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_ai_stocks\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 26 AI penny stocks</a> featuring innovators pushing AI boundaries.</li> <li>Secure consistent passive income and stability by focusing on <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/146/dividend-powerhouses-3-yield/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 21 dividend stocks with yields &gt; 3%</a> with yields above 3% to boost your returns.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:40:43",
            "link": "https://simplywall.st/stocks/jp/food-beverage-tobacco/tse-2914/japan-tobacco-shares/news/a-look-at-japan-tobacco-tse2914-valuation-after-dividend-hik",
            "image": "https://images.simplywall.st/asset/industry/5131000-choice1-main-header/1585186799809",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Fermi (FRMI) Is Up 44.3% After Securing Major Nuclear Partnerships and Incentives for Project Matador",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><ul> <li>Fermi America announced a series of transformative partnerships, including long-term nuclear supply and engineering agreements with Doosan Enerbility and Hyundai Engineering &amp; Construction, to advance its 11GW Project Matador private energy campus in Texas and secured key water and tax incentives from local government bodies.</li> <li>These developments uniquely position Fermi as a central player in the emerging intersection of energy infrastructure and AI data center growth, combining public and private support to accelerate U.S. energy and technology ambitions.</li> <li>We'll explore how Fermi’s nuclear collaborations strengthen its investment narrative and support its drive to power next-generation AI campuses.</li> </ul><p>The end of cancer? These <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/434428/ai-diagnosis/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 emerging AI stocks are developing tech that will allow early identification of life changing diseases</a> like cancer and Alzheimer's.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>What Is Fermi's Investment Narrative?</h2><p> For anyone considering Fermi as a potential holding, the investment case has always centered on its ambitious plan to build out a massive, private energy campus catering to the surging power needs of AI data centers. The latest series of announcements, including long-term nuclear collaborations and the lease of flexible gas turbines, significantly bolster the odds that Fermi can move from concept to initial power generation as early as 2026. These partnerships with global engineering leaders and supportive local government agreements address some of the biggest short-term execution risks by securing technology, fuel, water, and tax incentives, which were major question marks before. The near-term catalyst remains delivery of the first 500 MW of generation capacity, while successful project execution and revenue generation are now even more critical milestones. However, given Fermi’s lack of revenue, unproven business model, and very new management team, material risks still exist despite recent optimism and price gains driven largely by sentiment rather than underlying results.\nBut investors should remember: management experience remains a key issue for a business at this scale.\n</p> <a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/stocks/us/real-estate/nasdaq-frmi/fermi/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Our expertly prepared valuation report on Fermi</a> implies its share price may be too high.<h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/real-estate/nasdaq-frmi/fermi/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"FRMI Earnings &amp; Revenue Growth as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/cf0e1010-6f0a-428b-ae71-d75e592ca2cd/chart/earnings-and-revenue-growth\" width=\"746\"/></a><figcaption>FRMI Earnings &amp; Revenue Growth as at Oct 2025</figcaption></figure> Five fair value estimates from the Simply Wall St Community range from US$3.50 to US$35 per share. With views this spread, it’s clear opinions on Fermi’s true value are highly divided. At the same time, the real risk is not in the price but whether Fermi can deliver on its promises with so little track record. Explore where your perspective fits among this diverse group of investors.<p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/real-estate/nasdaq-frmi/fermi\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 5 other fair value estimates on Fermi</a> - why the stock might be worth as much as 22% more than the current price!</p><h2>Build Your Own Fermi Narrative</h2><p>Disagree with this assessment? <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://support.simplywall.st/hc/en-us/articles/10353275550479-Stock-Valuator-with-Narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Create your own narrative in under 3 minutes</a> - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Fermi research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/real-estate/nasdaq-frmi/fermi\" rel=\"noopener noreferrer\" target=\"_blank\">1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/real-estate/nasdaq-frmi/fermi\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Fermi research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Fermi's overall financial health at a glance.</li></ul><h2>Interested In Other Possibilities?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>Explore <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">28 top quantum computing companies</a> leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/global\" rel=\"noopener noreferrer\" target=\"_blank\">34 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/us\" rel=\"noopener noreferrer\" target=\"_blank\">companies with promising cash flow potential yet trading below their fair value</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:35:40",
            "link": "https://simplywall.st/stocks/us/real-estate/nasdaq-frmi/fermi/news/fermi-frmi-is-up-443-after-securing-major-nuclear-partnershi",
            "image": "https://images.simplywall.st/asset/company-cover/fallback-main-header/1585186798760",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent 50% Three-Month Share Price Rally",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\">Crinetics Pharmaceuticals (CRNX) shares have shown impressive movement over the past three months, rising 50 percent. Investors are watching closely as the company’s performance stands out in the biotechnology sector this quarter.\n<p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Crinetics Pharmaceuticals.</a></p> <p>Crinetics Pharmaceuticals has staged a remarkable turnaround after a tough start to the year. Over the last 90 days, the company has delivered a 50 percent share price gain, which stands in stark contrast to its 1-year total shareholder return of -23 percent. This momentum suggests renewed optimism around the company’s prospects, especially following some positive signals in the sector, and indicates that investor sentiment may be shifting in favor of future growth.</p> <p>Looking to discover more in the healthcare space? Now’s a great time to check out <a class=\"company-report-links\" data-vars-link-type=\"cta_healthcare_screener\" href=\"https://simplywall.st/discover/investing-ideas/7008/healthcare-sector/global\" rel=\"noopener noreferrer\" target=\"_blank\">See the full list for free.</a></p> <p>With such a rapid rebound, the big question facing investors is whether Crinetics Pharmaceuticals still has room to run or if the market has already anticipated this momentum, making further gains harder to come by.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Price-to-Book of 3.4x: Is it justified?</h2> <p>Crinetics Pharmaceuticals is currently trading at a price-to-book ratio of 3.4x, which falls below its peer average of 7x. This suggests the stock appears cheap relative to similar companies in the pharmaceuticals and biotech sector, based on this specific valuation metric.</p> <p>The price-to-book ratio is a commonly used measure for companies, especially in sectors where profits may not yet be material, like biotech. It compares a company's market value to its book value, offering a snapshot of how the market is assessing future growth potential or asset strength relative to peers.</p> <p>At 3.4x, Crinetics looks undervalued when contrasted with its peer group but more expensive than the broader US Pharmaceuticals industry average of 2.3x. This disparity may indicate that investors expect strong future growth from Crinetics, which could justify the premium to the wider industry, yet the valuation still lags behind top peers. However, keep in mind that Crinetics is currently unprofitable, and valuation based on book value rather than earnings is typical in early-stage biotech. If the market shifts its fair ratio expectations, the multiple could adjust accordingly.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price — find out in our valuation breakdown.</a></p> <p><strong>Result: Price-to-Book of 3.4x (UNDERVALUED)</strong></p> <p>However, investors must consider that unprofitability and sharp recent gains could bring volatility or swift sentiment reversals if expectations are not met.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Crinetics Pharmaceuticals narrative.</a></p> <h2>Another View: Discounted Cash Flow Perspective</h2> <p>Beyond simple book value comparisons, our DCF model values Crinetics Pharmaceuticals at $112.31 per share, well above its recent price of $42.90. This points to a much deeper undervaluation than what the price-to-book ratio suggests, but it also relies heavily on long-term growth projections that could shift rapidly. Which perspective will play out in the market?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"CRNX Discounted Cash Flow as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/cd6650c1-9d44-4ecf-8407-6794f93023a0/chart/dcf\" width=\"746\"/></a><figcaption>CRNX Discounted Cash Flow as at Oct 2025</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">check out Crinetics Pharmaceuticals for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/portfolio/demo\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows\" rel=\"noopener noreferrer\" target=\"_blank\">856 undervalued stocks based on their cash flows</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/screener/create\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2> Build Your Own Crinetics Pharmaceuticals Narrative</h2> <p>If you have a different perspective or would rather form your own view, you can analyze the numbers and assemble a narrative yourself in just minutes. <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative\" href=\"https://support.simplywall.st/hc/en-us/articles/10353275550479-Stock-Valuator-with-Narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Do it your way</a></p> <p>A great starting point for your Crinetics Pharmaceuticals research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 2 important warning signs</a> that could impact your investment decision.</p> <h2>Looking for more investment ideas?</h2> <p>Give your portfolio an edge by taking action on emerging opportunities outside the mainstream. Don’t wait until everyone catches on—these ideas could be tomorrow’s leaders.</p> <ul> <li>Capture steady income streams by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/146/dividend-powerhouses-3-yield/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 21 dividend stocks with yields &gt; 3%</a> with robust yields and financial health for reliable returns.</li> <li>Spot potential tech disruptors by investigating <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_ai_stocks\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 26 AI penny stocks</a> at the intersection of artificial intelligence and industry innovation.</li> <li>Seize value opportunities with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 856 undervalued stocks based on cash flows</a> signaling attractive prices relative to future growth prospects and cash flows.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:35:40",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crnx/crinetics-pharmaceuticals/news/assessing-crinetics-pharmaceuticals-crnx-valuation-after-rec",
            "image": "https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Lassila & Tikanoja (HLSE:LAT1V) Profit Margin Falls to 0.4%, Undermining Valuation Recovery Narrative",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><p>Lassila &amp; Tikanoja Oyj (HLSE:LAT1V) reported a notable fall in profitability, with net profit margin slipping to 0.4% this period from last year’s 3.2%. The company’s earnings have contracted by an average of 16.6% annually over the past five years, with a €22.0 million one-off loss weighing heavily on the bottom line. Investors are watching keenly, as shares currently trade at a price-to-earnings ratio of 136.7x, a significant premium to the industry and peer averages. Despite these challenges, earnings are forecast to rebound sharply, with 44.2% annual growth expected, outpacing the broader Finnish market even as revenue growth lags.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/fi/commercial-services/hel-lat1v/lassila-tikanoja-oyj-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for Lassila &amp; Tikanoja Oyj.</a> <p>The next step is to see how these results measure up when set against the key narratives shaping investor sentiment for Lassila &amp; Tikanoja. Some storylines may be confirmed, while others could be upended by the numbers.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_range_narrative\" href=\"https://www.simplywall.st/narratives/lmh3njcz-digitalization-and-regulatory-demand-will-drive-circular-economy-success-gz6e\" rel=\"noopener noreferrer\" target=\"_blank\">See what the community is saying about Lassila &amp; Tikanoja Oyj</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/fi/commercial-services/hel-lat1v/lassila-tikanoja-oyj-shares/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"HLSE:LAT1V Earnings &amp; Revenue History as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7e013f33-b5d9-46ce-bf77-2db92714c63d/chart/earnings-and-revenue-history\" width=\"746\"/></a><figcaption>HLSE:LAT1V Earnings &amp; Revenue History as at Oct 2025</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Planned Demerger Leaves Circular Economy Arm With €174m Debt Load</h2> <ul> <li> After the upcoming split, the new Circular Economy company will take on €174 million of the group’s net interest-bearing debt, nearly all of the €178 million total. This could significantly constrain investment flexibility and increase finance costs.\n  </li> <li> According to the analysts' consensus view, the high leverage post-demerger stands out as a material risk, challenging the company’s outlook for margin expansion and profit growth.\n    <ul> <li> Analysts highlight that exposure to higher interest costs may cut into future net margins and earnings, directly offsetting benefits from segment focus and improved efficiencies.\n      </li> <li> Persistently loss-making operations in Sweden add further drag, supporting the consensus caution that executing the turnaround plan remains an unresolved challenge.\n      </li> </ul> </li> </ul> <p>To see how debt strategy, margin targets, and structural changes fit into the big picture, catch the full consensus narrative for Lassila &amp; Tikanoja.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_consensus_narrative_link\" href=\"https://simplywall.st/narratives/lmh3njcz-digitalization-and-regulatory-demand-will-drive-circular-economy-success-gz6e\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>📊 Read the full Lassila &amp; Tikanoja Oyj Consensus Narrative.</strong></a> <h2>Forecasted Margin Climb From 0.5% to 6.4% by 2028</h2> <ul> <li> Analysts expect Lassila &amp; Tikanoja’s profit margin will rise from today’s 0.5% to 6.4% within three years. This potentially reverses the long decline but requires substantial improvement from current weak levels.\n  </li> <li> In line with the analysts' consensus view, this projected margin recovery is backed by the company’s shift toward digital platforms, expanding circular economy services, and recurring, long-term contracts.\n    <ul> <li> Full implementation of new ERP systems and digital tools is anticipated to drive efficiency, reduce costs, and support sustained margin expansion if execution stays on track.\n      </li> <li> The growth in sustainability-driven and data-led business lines is expected to increase recurring revenues and stabilize cash flow, both crucial for achieving higher profitability.\n      </li> </ul> </li> </ul> <h2>Premium Valuation: 136.7x P/E Versus DCF Fair Value of €30.76</h2> <ul> <li> Lassila &amp; Tikanoja shares currently trade at a 136.7x price-to-earnings ratio, far above both the European industry average (14.4x) and its peer group (23.6x). The DCF fair value is estimated at €30.76, roughly triple the latest share price of €10.02.\n  </li> <li> Analysts’ consensus narrative sees valuation tension. Although the stock is well below DCF fair value, analysts’ price target is just €10.50, only 4.8% above today’s price, reflecting skepticism around the pace of margin recovery and the risks to earnings quality.\n    <ul> <li> The consensus target implies analysts do not expect the stock to close the gap to DCF fair value soon, even if earnings growth outpaces the sector.\n      </li> <li> For value-focused investors, the key debate is whether operational execution and margin expansion can deliver enough upside to justify the premium multiple.\n      </li> </ul> </li> </ul> <h2> Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://www.simplywall.st/narratives/lmh3njcz-digitalization-and-regulatory-demand-will-drive-circular-economy-success-gz6e\" rel=\"noopener noreferrer\" target=\"_blank\">community narratives</a> for Lassila &amp; Tikanoja Oyj on Simply Wall St. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/portfolio/demo\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> so you'll be alerted when the story evolves.</p> <p>Have another take on what the results mean? Turn your unique angle into a fresh narrative in just a few minutes with <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative\" href=\"https://support.simplywall.st/hc/en-us/articles/10353275550479-Stock-Valuator-with-Narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Do it your way</a>.</p> <p>A great starting point for your Lassila &amp; Tikanoja Oyj research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/fi/commercial-services/hel-lat1v/lassila-tikanoja-oyj-shares\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 4 important warning signs</a> that could impact your investment decision.</p> <h2>See What Else Is Out There</h2> <p>Lassila &amp; Tikanoja faces uncertainty due to high debt after the planned demerger, margin pressure, and skepticism about its premium valuation.</p> <p>If you want companies with stronger finances and less debt risk, check out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/global\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (1988 results)</a> to find those better positioned for financial resilience.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:35:40",
            "link": "https://simplywall.st/stocks/fi/commercial-services/hel-lat1v/lassila-tikanoja-oyj-shares/news/lassila-tikanoja-hlselat1v-profit-margin-falls-to-04-undermi",
            "image": "https://images.simplywall.st/asset/industry/3114000-choice2-main-header/1585186838280",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Axactor (OB:ACR): Five-Year Losses Deepen Despite Revenue Growth, Challenging Bullish Outlook",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><p>Axactor (OB:ACR) reported that losses have accelerated over the last five years, growing at an average annual rate of 19.7%. However, revenue is forecast to expand by 16.7% per year, a pace that stands out against the broader Norwegian market's 2.8% annual growth. The company's Price-To-Sales Ratio of 1.3x remains below key industry benchmarks. Investors will notice that despite sales momentum, persistent negative profitability and shares trading above the estimated fair value (NOK7.1 vs NOK4.24) frame a complex earnings picture.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/no/diversified-financials/ob-acr/axactor-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for Axactor.</a> <p>Next up, we’ll see how these headlines compare to the prevailing narratives at Simply Wall St. We will also consider whether the numbers reinforce or challenge the consensus story.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_range_narrative\" href=\"https://www.simplywall.st/narratives/5lqvn1ju-new-npl-and-digital-investments-will-transform-european-markets-9b9e\" rel=\"noopener noreferrer\" target=\"_blank\">See what the community is saying about Axactor</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/no/diversified-financials/ob-acr/axactor-shares/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"OB:ACR Earnings &amp; Revenue History as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/cb17aa95-925c-44ac-9731-591572a85cdb/chart/earnings-and-revenue-history\" width=\"746\"/></a><figcaption>OB:ACR Earnings &amp; Revenue History as at Oct 2025</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Margin Expansion Hinges on Cost Control</h2> <ul> <li>Interest expenses on new bonds dropped by more than 3 percentage points due to successful refinancing, and ongoing IT-driven cost reductions (€800,000 saved per quarter) are aiming to boost Axactor's free cash flow and net profitability.</li> <li>According to the analysts' consensus view, disciplined cost management and the rollout of digital collection platforms are set to drive margin gains, with net margins forecast to climb from -49.6% to 21.9% over the next three years.\n    <ul> <li>Consensus narrative notes that new third-party collection contracts, especially in Norway, could accelerate revenue and margin growth in 2026–2027 if cost savings materialize as planned.</li> <li>What is surprising is that despite flat revenue growth in certain regions and recent margin pressure from onboarding costs, consensus expects efficiency initiatives and a larger addressable market to materially lift profitability.</li> </ul> </li> </ul> <p>See where analysts agree and disagree on whether Axactor’s efficiency push is enough to drive sustainable profit improvements. <a class=\"company-report-links\" data-vars-link-type=\"cta_consensus_narrative_link\" href=\"https://simplywall.st/narratives/5lqvn1ju-new-npl-and-digital-investments-will-transform-european-markets-9b9e\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>📊 Read the full Axactor Consensus Narrative.</strong></a></p> <h2>Market Share Upside Tied to NPL Investments</h2> <ul> <li>Axactor is strategically investing in new non-performing loan (NPL) portfolios, aiming to capture a bigger share of Europe’s growing consumer debt market and capitalize on a strong NPL disposal pipeline.</li> <li>Consensus narrative highlights that management’s pivot toward acquiring new NPLs, combined with proprietary analytics and IT upgrades, positions Axactor for improved collection performance and higher future revenues.\n    <ul> <li>Consensus view emphasizes the large-scale third-party collection contracts and recently extended debt maturities into 2027–2028 as supporting longer-term growth ambitions.</li> <li>Bears argue that if flat year-over-year gross revenues (down 9% overall, down 1% excluding the Spain sale) persist due to a more “normalized” market, hoped-for NPL-related gains could fall short.</li> </ul> </li> </ul> <h2>Valuation Discount Faces Profitability Hurdles</h2> <ul> <li>Axactor’s Price-To-Sales Ratio of 1.3x is lower than both its peer average (3x) and the broader Consumer Finance industry (1.7x), but the current share price (NOK7.1) still trades above DCF fair value (NOK4.24) and below the analyst target (NOK10.00), revealing a tension between quantitative cheapness and earnings uncertainty.</li> <li>Consensus narrative calls out that to justify the analyst target price, Axactor needs to grow annual revenue to €317.5 million and convert losses of €-67.6 million to €69.5 million in profit within four years, a significant turnaround embedded into current forecasts.\n    <ul> <li>This expectation leans on higher margins, steady share count, and a future PE ratio of 5.1x, meaning risk remains if margin expansion or revenue targets are missed against industry headwinds and competition.</li> <li>Investors are encouraged to cross-check these optimistic forecasts against their own outlook, as the stock currently trades in the limbo between promising multiples and persistent losses.</li> </ul> </li> </ul> <h2> Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://www.simplywall.st/narratives/5lqvn1ju-new-npl-and-digital-investments-will-transform-european-markets-9b9e\" rel=\"noopener noreferrer\" target=\"_blank\">community narratives</a> for Axactor on Simply Wall St. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/portfolio/demo\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> so you'll be alerted when the story evolves.</p> <p>Looking at the figures from another angle? In just a few minutes, you can share your own take and add it to the story. <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative\" href=\"https://support.simplywall.st/hc/en-us/articles/10353275550479-Stock-Valuator-with-Narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Do it your way</a></p> <p>A great starting point for your Axactor research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/no/diversified-financials/ob-acr/axactor-shares\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 1 important warning sign</a> that could impact your investment decision.</p> <h2>See What Else Is Out There</h2> <p>While Axactor’s revenue prospects have improved, ongoing losses and challenges in achieving sustainable profitability create real uncertainty around a turnaround.</p> <p>If you want more reliable growth and less earnings risk, use <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_stable_growth\" href=\"https://simplywall.st/discover/investing-ideas/372939/stable-growth-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">stable growth stocks screener (2119 results)</a> to focus on companies consistently delivering steady results year after year.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:35:39",
            "link": "https://simplywall.st/stocks/no/diversified-financials/ob-acr/axactor-shares/news/axactor-obacr-five-year-losses-deepen-despite-revenue-growth",
            "image": "https://images.simplywall.st/asset/industry/7121000-choice2-main-header/1585186688507",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Yokogawa Bridge Holdings (TSE:5911) Profit Margin Beats, Reinforcing Value Narrative Despite Dividend Concerns",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><p>Yokogawa Bridge Holdings (TSE:5911) delivered a net profit margin of 7.9%, up from last year's 6.2%, with EPS growth coming in at 29.2% over the past year. This is well above the company's five-year annual average of 1%. Shares are trading at 8.9x earnings, notably below sector and peer averages, while profit and revenue trends point to a solid footing for the business. The spotlight is now on whether the company can sustain this profitability momentum as it moves forward.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/jp/capital-goods/tse-5911/yokogawa-bridge-holdings-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for Yokogawa Bridge Holdings.</a> <p>Next up, we will see how these headline numbers stack up against the bigger market narratives, highlighting which views are reinforced and where surprises might be emerging.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/jp/capital-goods/tse-5911/yokogawa-bridge-holdings-shares/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSE:5911 Revenue &amp; Expenses Breakdown as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/3fe96adb-ca0b-4a6c-9c59-a29b20c61cdf/chart/revenue-and-expenses-breakdown\" width=\"746\"/></a><figcaption>TSE:5911 Revenue &amp; Expenses Breakdown as at Oct 2025</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Revenue Forecasts Outpace Market Norms</h2> <ul> <li>Yokogawa Bridge Holdings is forecasting annual revenue growth of 6.7%, well ahead of the broader Japanese market’s forecasted 4.5% growth rate.</li> <li>Extending the prevailing market view, this above-average revenue outlook supports the idea that the company’s specialized role in infrastructure allows it to outperform more generalized peers.\n    <ul> <li>Analysts will be watching to see if consistent government and maintenance projects can keep driving this stronger trajectory, especially as sector momentum remains steady but unspectacular overall.</li> <li>With growth anchored in reliable, long-term contracts instead of hype, upside for patient investors may depend on the company converting forecasts into realized gains over multiple years.</li> </ul> </li> </ul> <h2>Affordable Valuation Against Sector and Peers</h2> <ul> <li>Trading at just 8.9 times earnings, Yokogawa Bridge Holdings sits meaningfully below the industry average of 12.3x and its peers at 48.1x. Its current share price of 2772.00 is well below its DCF fair value estimate of 5237.79.</li> <li>Building on the prevailing market view, this discount highlights an under-the-radar opportunity for investors who focus on value rather than chasing momentum.\n    <ul> <li>Bulls argue that defensive infrastructure names like Yokogawa Bridge often attract a premium, so its current valuation could appeal to buyers seeking safety and capital preservation.</li> <li>On the other hand, some caution that the lack of a strong price premium may reflect low near-term excitement, leaving prospective investors to balance stability against potential for fast gains.</li> </ul> </li> </ul> <h2>Dividend Sustainability Remains a Key Watchpoint</h2> <ul> <li>The primary risk flagged is around the sustainability of Yokogawa Bridge’s dividend, which moderates enthusiasm given the company’s otherwise steady performance trends.</li> <li>In line with the prevailing market view, this risk echoes a broader pattern seen in the infrastructure sector where headline profits are solid but payout ratios or future distributions require close monitoring.\n    <ul> <li>Loyal income-focused investors are attracted by the company’s stable record, yet persistent questions on dividend security could limit share price upside if not addressed.</li> <li>Ongoing improvements in profit margins may help mitigate this risk, but a clear dividend commitment will remain central for shareholder confidence going forward.</li> </ul> </li> </ul> <h2> Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Yokogawa Bridge Holdings's <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://www.simplywall.st/stocks/jp/capital-goods/tse-5911/yokogawa-bridge-holdings-shares/past\" rel=\"noopener noreferrer\" target=\"_blank\">growth</a> and its <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://www.simplywall.st/stocks/jp/capital-goods/tse-5911/yokogawa-bridge-holdings-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">valuation</a> to see if today's price is a bargain. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://simplywall.st/portfolio/demo\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> now so you don't miss the next big move.</p> <h2>See What Else Is Out There</h2> <p>Despite solid profits, questions around Yokogawa Bridge’s dividend sustainability present a potential risk for investors seeking safe and growing income streams.</p> <p>If you want more dependable and higher-yielding income ideas, consider focusing on <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/146/dividend-powerhouses-3-yield/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 2002 dividend stocks with yields &gt; 3%</a> that match your dividend priorities and offer greater peace of mind.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:31:01",
            "link": "https://simplywall.st/stocks/jp/capital-goods/tse-5911/yokogawa-bridge-holdings-shares/news/yokogawa-bridge-holdings-tse5911-profit-margin-beats-reinfor",
            "image": "https://images.simplywall.st/asset/industry/3041000-choice2-main-header/1585186777117",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Nifco (TSE:7988) Valuation: Assessing the Impact After Completion of Share Buyback Program",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><p>Nifco (TSE:7988) wrapped up its latest share buyback plan on October 30, 2025, after acquiring just over 1.19 million shares, which is about 1.3% of its outstanding stock during the program.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7988/nifco-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Nifco.</a></p> <p>Nifco wrapped up its share buyback program just as momentum has been building in the stock. The company saw a 19.8% share price return over the last 90 days and a one-year total shareholder return of nearly 30%. This solid run, helped by management’s recent move, suggests investors are viewing the company more favorably and could be reassessing its longer-term potential in the auto parts sector.</p> <p>If you want to see what other auto stocks are catching investors’ attention, now’s a perfect time to explore <a class=\"company-report-links\" data-vars-link-type=\"cta_auto_manufacturers_screener\" href=\"https://simplywall.st/discover/investing-ideas/426622/auto-manufacturers/global\" rel=\"noopener noreferrer\" target=\"_blank\">See the full list for free.</a></p> <p>With shares up this year and buybacks complete, does Nifco still trade at a discount to its intrinsic worth, or is the recent optimism already reflected in the stock price, leaving little room for further upside?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Price-to-Earnings of 9.4x: Is it justified?</h2> <p>Nifco currently trades on a price-to-earnings (P/E) ratio of 9.4x, noticeably cheaper than peers and industry averages. With a last close price of ¥4,567, the market is valuing its earnings at a significant discount to both the broader market and its sector.</p> <p>The price-to-earnings ratio measures how much investors are willing to pay today for a yen of current earnings. For established auto parts companies like Nifco, the P/E offers a clear lens into market expectations for future profit growth or risk.</p> <p>Nifco’s low P/E suggests investors may be underappreciating its recent profit surge. While the stock sits well below the peer average of 16.4x and the Japanese auto components industry average of 11.6x, its trailing earnings growth has been impressive. However, forecasts point to less optimistic profit trends in coming years. This could be tempering the multiple assigned by the market.</p> <p>It is helpful to compare this 9.4x P/E not only to competitors, but also to what analysts deem a “fair” multiple for Nifco. The estimated fair price-to-earnings ratio is 8.4x, indicating the stock looks a bit expensive on this metric. The market’s enthusiasm may be pushing it closer to, or slightly above, its justified level based on recent performance and expected outlook.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"fair_ratio_cta\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7988/nifco-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Explore the SWS fair ratio for Nifco</a></p> <p><strong>Result: Price-to-Earnings of 9.4x (UNDERVALUED)</strong></p> <p>However, slower net income growth and a smaller discount to analyst price targets could weigh on sentiment if profitability does not meet expectations.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7988/nifco-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Nifco narrative.</a></p> <h2>Another View: Discounted Cash Flow Says \"Undervalued\"</h2> <p>Looking at Nifco through the lens of our DCF model tells a different story. The analysis suggests shares are trading at a significant 33% discount to fair value, which means today's market price may understate the true worth of the business. Could this gap signal a bigger long-term opportunity, or is there more risk beneath the surface?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7988/nifco-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/automobiles/tse-7988/nifco-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"7988 Discounted Cash Flow as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/6a18c310-0277-44fe-be5a-62f6a257ada1/chart/dcf\" width=\"746\"/></a><figcaption>7988 Discounted Cash Flow as at Oct 2025</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7988/nifco-shares\" rel=\"noopener noreferrer\" target=\"_blank\">check out Nifco for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/portfolio/demo\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows\" rel=\"noopener noreferrer\" target=\"_blank\">856 undervalued stocks based on their cash flows</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/screener/create\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2> Build Your Own Nifco Narrative</h2> <p>If you want to dig into the numbers yourself or see things from a different angle, you can quickly craft your own narrative using our tools. <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative\" href=\"https://support.simplywall.st/hc/en-us/articles/10353275550479-Stock-Valuator-with-Narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Do it your way</a>.</p> <p>A great starting point for your Nifco research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7988/nifco-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> that could impact your investment decision.</p> <h2>Looking for more investment ideas?</h2> <p>Act now to get ahead of the market and turn market shifts into opportunities with smart strategies. Don’t let standout investment trends pass you by.</p> <ul> <li>Target impressive yields for your portfolio and tap into growth with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/146/dividend-powerhouses-3-yield/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 21 dividend stocks with yields &gt; 3%</a>, which consistently outperform in both income and stability.</li> <li>Join the AI revolution and boost your edge by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_ai_stocks\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 26 AI penny stocks</a>, as they are redefining industry boundaries with transformative applications.</li> <li>Spot undervalued gems waiting for smart investors. Seize your chance now with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 856 undervalued stocks based on cash flows</a> before the crowd catches on.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:31:01",
            "link": "https://simplywall.st/stocks/jp/automobiles/tse-7988/nifco-shares/news/nifco-tse7988-valuation-assessing-the-impact-after-completio",
            "image": "https://images.simplywall.st/asset/industry/4012000-choice1-main-header/1585186661661",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Wingstop (WING): Exploring Valuation After Recent Share Price Weakness",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><p>Wingstop (WING) shares have seen shifts over the past month, with recent trading reflecting a 4% dip. Investors may be evaluating the company’s longer-term trends and current valuation as the broader restaurant sector navigates ongoing challenges.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nasdaq-wing/wingstop\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Wingstop.</a></p> <p>While Wingstop’s shares have seen pressure lately, with the 1-month share price return at -3.6% and the 90-day return at -33%, the longer-term story remains more upbeat, as total shareholder returns over five years sit above 100%. After a period of strong momentum, recent declines suggest that market sentiment is cooling for now. This has prompted a closer look at the company’s fundamentals and growth outlook.</p> <p>If you're weighing your next move, it could be the right moment to broaden your search and discover <a class=\"company-report-links\" data-vars-link-type=\"cta_fast_growing_high_insider_ownership_screener\" href=\"https://simplywall.st/discover/investing-ideas/10228/fast-growing-stocks-with-high-insider-ownership/global\" rel=\"noopener noreferrer\" target=\"_blank\">fast growing stocks with high insider ownership</a></p> <p>With shares down from their highs but robust long-term returns on the table, investors may wonder if recent weakness means Wingstop is trading at a bargain or if the market has already factored in its future growth prospects.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Most Popular Narrative: 32.9% Undervalued</h2> <p>Wingstop's most widely followed narrative places its fair value far above the recent close, hinting at significant upside if growth plays out as analysts expect. The current market price trails this narrative’s long-term convictions, which sets the stage for investors to dig deeper into the reasoning behind this optimistic outlook.</p> <blockquote> <p><em>Accelerated global unit development, fueled by record-high franchisee returns and unprecedented brand partner reinvestment, is expanding Wingstop's footprint in both established and underpenetrated international markets. This positions the company for substantial systemwide sales growth and a rising share of high-margin franchise fee revenue.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/5i0ew51p-digital-platform-rollout-and-international-expansion-will-drive-efficiency-2cgn\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Want to know why analysts say Wingstop could massively expand its profits and dominate new markets? The secret? It’s not just about more store openings; it is also about the bold, forward-looking numbers fueling this narrative’s fair value. Ready to see the assumptions that support this bullish price target?</p> <p><strong>Result: Fair Value of $361.75 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/5i0ew51p-digital-platform-rollout-and-international-expansion-will-drive-efficiency-2cgn\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, if softer demand among key consumer groups and limited menu innovation persist, these trends could threaten the pace of Wingstop's growth.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nasdaq-wing/wingstop\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Wingstop narrative.</a></p> <h2>Another View: Comparing Market Ratios</h2> <p>While analyst forecasts suggest Wingstop is undervalued, our market ratios tell a different story. The company's current price-to-earnings ratio stands at 39.5 times, which is much higher than the fair ratio of 20 and the industry average of 23.7. This pricing may limit the margin of safety if market growth falters. Could the current premium point to risk ahead?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nasdaq-wing/wingstop/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price — find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/consumer-services/nasdaq-wing/wingstop/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:WING PE Ratio as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/2fb81df4-eb71-4bf0-96c1-c9f7dadf1da2/chart/pe-multiple-vs-industry\" width=\"746\"/></a><figcaption>NasdaqGS:WING PE Ratio as at Oct 2025</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nasdaq-wing/wingstop\" rel=\"noopener noreferrer\" target=\"_blank\">check out Wingstop for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/portfolio/demo\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows\" rel=\"noopener noreferrer\" target=\"_blank\">856 undervalued stocks based on their cash flows</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/screener/create\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2> Build Your Own Wingstop Narrative</h2> <p>If you'd rather take the reins and craft your own perspective from the numbers, you can start building a personal narrative in just a few minutes. <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative\" href=\"https://support.simplywall.st/hc/en-us/articles/10353275550479-Stock-Valuator-with-Narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Do it your way</a></p> <p>A great starting point for your Wingstop research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nasdaq-wing/wingstop\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 4 important warning signs</a> that could impact your investment decision.</p> <h2>Looking for More Standout Investment Ideas?</h2> <p>Hundreds of promising companies are out there waiting to be found. Don’t miss out on ground-floor opportunities, bold new trends, or reliable income plays. Simply Wall Street’s Screener makes it easy.</p> <ul> <li>Unlock stocks offering robust yields and stable income streams by browsing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/146/dividend-powerhouses-3-yield/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 21 dividend stocks with yields &gt; 3%</a> with yields above 3%.</li> <li>Tap into the next wave of innovation by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_ai_stocks\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 26 AI penny stocks</a> making headlines with artificial intelligence breakthroughs.</li> <li>Strengthen your portfolio with strong value opportunities by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 856 undervalued stocks based on cash flows</a> based on future cash flows.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:31:01",
            "link": "https://simplywall.st/stocks/us/consumer-services/nasdaq-wing/wingstop/news/wingstop-wing-exploring-valuation-after-recent-share-price-w",
            "image": "https://images.simplywall.st/asset/industry/4214000-choice1-main-header/1585186691957",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "SpareBank 1 SMN (OB:MING) Margins Edge Higher, Underscoring Profit Consistency Against Slower Growth Narratives",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><p>SpareBank 1 SMN (OB:MING) posted robust results for the period, with net profit margins edging up to 34.4% from 33.5% a year ago. Over the past five years, earnings have grown at a healthy 19.8% per year, though most recent annual earnings growth eased to 3.9%. Investors will find it notable that the shares are priced attractively, with a PE ratio of 8.6x, which is well below both the sector average and the company is trading under its estimated fair value at NOK 188.76. Looking ahead, forecasts point to earnings growth of 6.7% per year and revenue growth of 0.7% per year. Both figures trail the broader Norwegian market, but the company’s reputation for high-quality, consistent profits keeps sentiment positive.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/no/banks/ob-ming/sparebank-1-smn-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for SpareBank 1 SMN.</a> <p>The next section sets these results against the widely held narratives for SpareBank 1 SMN and highlights where the numbers support market sentiment and where the story could shift.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/no/banks/ob-ming/sparebank-1-smn-shares/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"OB:MING Earnings &amp; Revenue History as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/1eeee88b-f278-45ee-a354-e09c3449e191/chart/earnings-and-revenue-history\" width=\"746\"/></a><figcaption>OB:MING Earnings &amp; Revenue History as at Oct 2025</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Margins Stay Elevated Despite Slowing Growth</h2> <ul> <li>Net profit margins came in at 34.4%, just ahead of last year’s 33.5%, which confirms profitability has held firm even as annual earnings growth slowed to 3.9% from the five-year annualized 19.8% pace.</li> <li> Strong margins support the idea that SpareBank 1 SMN’s business model is resilient and continues to generate dependable profits, even when overall growth cools.\n    <ul> <li>The period’s margin improvement, although modest, strongly reinforces optimism about management’s ability to maintain efficiency and pricing power in a slower market.</li> <li>Bulls highlight that consistent profit margins make the company more dependable compared to rivals that might be more sensitive to economic swings.</li> </ul> </li> </ul> <h2>Peer-Relative Valuation Points to Upside</h2> <ul> <li>The price-to-earnings ratio of 8.6x is noticeably below both the industry’s 10.7x and peer group’s 9.8x, while the share price of NOK 188.76 sits well beneath the DCF fair value estimate of NOK 297.77.</li> <li> The valuation gap stands out as a key reason some investors consider SpareBank 1 SMN undervalued, even with growth expected to trail the broader Norwegian market.\n    <ul> <li>With the bank trading at these lower multiples, market participants may see both a margin of safety and room for re-rating if fundamentals remain stable.</li> <li>However, since top-line growth is only forecast at 0.7% per year, bulls are careful to ground their optimism in the quality and consistency of underlying earnings rather than betting on a big step-up in revenue.</li> </ul> </li> </ul> <h2>Consistent Profitability Supports Dividend and Value Strength</h2> <ul> <li>Reported earnings have grown by an average of 19.8% per year over the past five years, coupled with several confirmed rewards in quality and dividend reliability according to company risk/reward data.</li> <li> The prevailing narrative centers on SpareBank 1 SMN’s reputation for delivering steady profits and rewarding income-focused investors, which is reinforced by the lack of flagged risks.\n    <ul> <li>Many observers see the track record for durable growth and stable payouts as a powerful reason for continued confidence at current price levels.</li> <li>The absence of major risks in recent filings, when considered alongside robust historical earnings, makes the overall investment case stronger, though investors will still watch for any signs of a shift in operating conditions.</li> </ul> </li> </ul> <p>To see deeper analysis and insights on SpareBank 1 SMN, check out the full balanced narrative for more context on these numbers. <a href=\"?utm_medium=finance_user&amp;utm_campaign=cta_consensus_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>📊 Read the full SpareBank 1 SMN Consensus Narrative.</strong></a></p> <h2> Next Steps</h2> <p>Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on SpareBank 1 SMN's <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://www.simplywall.st/stocks/no/banks/ob-ming/sparebank-1-smn-shares/past\" rel=\"noopener noreferrer\" target=\"_blank\">growth</a> and its <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://www.simplywall.st/stocks/no/banks/ob-ming/sparebank-1-smn-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">valuation</a> to see if today's price is a bargain. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_dont_exist\" href=\"https://simplywall.st/portfolio/demo\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> now so you don't miss the next big move.</p> <h2>See What Else Is Out There</h2> <p>With revenue and earnings growth projected to lag behind the wider Norwegian market, SpareBank 1 SMN’s upside may appear limited for aggressive growth seekers.</p> <p>If you want to focus on businesses forecast for stronger financial acceleration, our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_large_cap_high_growth_potential\" href=\"https://simplywall.st/discover/investing-ideas/5594/high-growth-potential/global\" rel=\"noopener noreferrer\" target=\"_blank\">high growth potential stocks screener (62 results)</a> can help you discover established names targeting higher growth over the next few years.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:31:01",
            "link": "https://simplywall.st/stocks/no/banks/ob-ming/sparebank-1-smn-shares/news/sparebank-1-smn-obming-margins-edge-higher-underscoring-prof",
            "image": "https://images.simplywall.st/asset/industry/7013000-choice2-main-header/1585186648241",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Lowe’s (LOW) Valuation: Is There Untapped Value After Recent Share Price Dip?",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\">Lowe's Companies (LOW) stock has seen some shifts in recent weeks, prompting investors to pay closer attention to its longer-term trends and valuation. The company continues to navigate a competitive home improvement landscape with solid fundamentals.\n<p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-low/lowes-companies\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Lowe's Companies.</a></p> <p>Lowe's share price has given up some ground recently, sliding 5.85% over the past month, while its year-to-date move is now in the red. However, the longer-term picture shows the company still boasts a healthy 36% total return over three years and 55% over five years. This suggests that while momentum is shaky right now, long-term investors have been well rewarded.</p> <p>If you're interested in spotting more resilient performers beyond giants like Lowe's, this is a prime opportunity to discover <a class=\"company-report-links\" data-vars-link-type=\"cta_fast_growing_high_insider_ownership_screener\" href=\"https://simplywall.st/discover/investing-ideas/10228/fast-growing-stocks-with-high-insider-ownership/global\" rel=\"noopener noreferrer\" target=\"_blank\">fast growing stocks with high insider ownership</a></p> <p>With the stock currently trading about 18% below analyst price targets, the question now is whether Lowe's still has untapped value or if its future growth prospects are already fully reflected in the share price.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Most Popular Narrative: 15.4% Undervalued</h2> <p>Lowe’s most popular narrative places its fair value at $281.84, about $43 ahead of its last close at $238.49. The stage is set as bullish analysts point to digital expansions and strategic acquisitions as a powerful formula the current share price may not fully reflect.</p> <blockquote> <p><em>The acquisition of Foundation Building Materials (FBM) sharply accelerates Lowe's access to the large Pro contractor market, especially in key underserved regions (California, Northeast, Midwest), unlocking new revenue streams, greater ticket sizes, and a larger share of the $250 billion Pro market, which is expected to drive above-market sales growth and improved diversification of revenue over the coming years.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/td0jboul-digital-tools-and-acquisitions-will-capture-underserved-pro-markets-shbp\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>What’s the secret fuel behind this double-digit upside? Insiders are betting on transformative margin gains, scale-driven bargaining power, and a profit trajectory that rivals major disruptors. Want to see which numbers bold analysts are actually using in their math? Dive into the narrative and discover what could tip the scales for Lowe’s future value.</p> <p><strong>Result: Fair Value of $281.84 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/td0jboul-digital-tools-and-acquisitions-will-capture-underserved-pro-markets-shbp\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, integration missteps from recent acquisitions or persistent labor cost pressures could undermine Lowe's profit margins and challenge the growth narrative.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-low/lowes-companies\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Lowe's Companies narrative.</a></p> <h2>Another View: SWS DCF Model Challenges the Upside</h2> <p>While analyst consensus suggests Lowe’s is undervalued, our SWS DCF model tells a different story. Based on projected cash flows, it estimates a fair value closer to $144.85, which is far below the current share price. Could the market be too optimistic about future growth and margin expansion?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-low/lowes-companies/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/retail/nyse-low/lowes-companies/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"LOW Discounted Cash Flow as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/2d04f03c-c3ce-443d-a146-1b58d3087655/chart/dcf\" width=\"746\"/></a><figcaption>LOW Discounted Cash Flow as at Oct 2025</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-low/lowes-companies\" rel=\"noopener noreferrer\" target=\"_blank\">check out Lowe's Companies for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/portfolio/demo\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows\" rel=\"noopener noreferrer\" target=\"_blank\">856 undervalued stocks based on their cash flows</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/screener/create\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2> Build Your Own Lowe's Companies Narrative</h2> <p>If you want to take a more hands-on approach or bring a different perspective to the table, it's fast and simple to craft your own view. <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative\" href=\"https://support.simplywall.st/hc/en-us/articles/10353275550479-Stock-Valuator-with-Narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Do it your way</a>.</p> <p>A great starting point for your Lowe's Companies research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-low/lowes-companies\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 3 important warning signs</a> that could impact your investment decision.</p> <h2>Looking for More Investment Ideas?</h2> <p>Smart investors never limit themselves to just one stock or sector. Expand your portfolio's potential by uncovering top-rated stocks for 2024 with tailored screeners from Simply Wall Street.</p> <ul> <li>Supercharge your returns and access exclusive opportunities by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 856 undervalued stocks based on cash flows</a> that analysts believe are trading below their true worth right now.</li> <li>Capture tomorrow’s growth by finding <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_ai_stocks\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 26 AI penny stocks</a> already making waves in artificial intelligence applications across multiple industries.</li> <li>Boost your income with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/146/dividend-powerhouses-3-yield/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 21 dividend stocks with yields &gt; 3%</a> designed to spotlight strong yields and reliable payouts above 3%, so you never miss a cash-generating winner.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:25:47",
            "link": "https://simplywall.st/stocks/us/retail/nyse-low/lowes-companies/news/lowes-low-valuation-is-there-untapped-value-after-recent-sha",
            "image": "https://images.simplywall.st/asset/company-cover/180871-main-header/1756209614998",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "What Schneider Electric (ENXTPA:SU)'s Data Center Power Push and Guidance Update Means For Shareholders",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><ul> <li>Schneider Electric recently reaffirmed its 2025 earnings guidance, anticipating organic revenue growth of 7% to 10%, and announced several product and executive updates, including a collaboration with NVIDIA to develop advanced 800 VDC power systems for high-density data centers.</li> <li>The company's focus on innovation in renewable energy applications and data center power solutions underscores its commitment to meeting emerging industry demands while supporting sustainability and digital transformation.</li> <li>We'll review how Schneider Electric's robust guidance and advancements in data center power architecture may influence its investment narrative.</li> </ul><p>These <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/434411/trump-tariffs/global\" rel=\"noopener noreferrer\" target=\"_blank\">11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs</a>. Discover why before your portfolio feels the trade war pinch.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Schneider Electric Investment Narrative Recap</h2><p>Grounded in global electrification and digitalization, Schneider Electric’s investment narrative centers on its capacity to capture long-term opportunity in data center growth, energy management, and sustainability. The company’s reaffirmed 2025 guidance and recent product news are welcome, but do not materially change the critical short-term catalyst: sustained momentum and margin resilience in high-growth digital infrastructure, despite margin pressures from mix headwinds and heavy reinvestment that remain top near-term risks.</p> <p>The launch of Altivar Solar ATV320 variable speed drives, designed for off-grid solar-powered pumping, is particularly relevant amid Schneider’s focus on the expanding renewables market. This product extension sharpens the company's positioning as a solution provider in energy efficiency, which ties directly to the evolving catalysts around energy transition and grid modernization.</p> <p>On the other hand, continued margin pressure in the Systems segment could create a headwind that investors should be aware of, especially if...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/fr/capital-goods/epa-su/schneider-electric-shares/1io1x542-ai-computing-and-renewable-trends-will-spark-global-transformation-06od\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Schneider Electric (it's free!)</a></p><p>Schneider Electric's outlook anticipates €48.6 billion in revenue and €6.7 billion in earnings by 2028. This implies a 7.3% annual revenue growth rate and a €2.4 billion earnings increase from the current €4.3 billion.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/fr/capital-goods/epa-su/schneider-electric-shares/1io1x542-ai-computing-and-renewable-trends-will-spark-global-transformation-06od\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Schneider Electric's forecasts yield a €260.64 fair value</a>, a 5% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/fr/capital-goods/epa-su/schneider-electric-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ENXTPA:SU Community Fair Values as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/36b307e5-42b4-46f7-b52d-1b782f71a2a7/chart/community-fair-value\" width=\"746\"/></a><figcaption>ENXTPA:SU Community Fair Values as at Oct 2025</figcaption></figure> <p>Simply Wall St Community members mapped Schneider Electric’s fair value estimates from €141.49 to €261.12, with 7 different viewpoints represented. While data center demand remains a catalyst, opinions on future performance are far from uniform, so reviewing the full range of forecasts may offer broader context.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/fr/capital-goods/epa-su/schneider-electric-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 7 other fair value estimates on Schneider Electric</a> - why the stock might be worth 43% less than the current price!</p><h2>Build Your Own Schneider Electric Narrative</h2><p>Disagree with existing narratives? <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://support.simplywall.st/hc/en-us/articles/10353275550479-Stock-Valuator-with-Narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Create your own in under 3 minutes</a> - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Schneider Electric research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/fr/capital-goods/epa-su/schneider-electric-shares\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/fr/capital-goods/epa-su/schneider-electric-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Schneider Electric research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Schneider Electric's overall financial health at a glance.</li></ul><h2>Ready To Venture Into Other Investment Styles?</h2><p>These stocks are moving-our analysis flagged them today. Act fast before the price catches up:</p><ul><li>We've found <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434616/us-dividend-powerhouses-with-a-forecast-yield-of-6percent/global\" rel=\"noopener noreferrer\" target=\"_blank\">21 US stocks that are forecast to pay a dividend yield of over 6% next year</a>. See the full list for free.</li><li>Explore <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">28 top quantum computing companies</a> leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li><li>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/415368/financially-fit-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">financially sound penny stocks that balance risk and reward</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:25:47",
            "link": "https://simplywall.st/stocks/fr/capital-goods/epa-su/schneider-electric-shares/news/what-schneider-electric-enxtpasus-data-center-power-push-and",
            "image": "https://images.simplywall.st/asset/industry/3051000-choice1-main-header/1585186568557",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Fresh Look at Autodesk (ADSK) Valuation After Recent Share Price Pullback",
            "description": "<div class=\"sc-e15375e9-4 fgtIxR\" data-cy-id=\"article-content\"><p>Autodesk (ADSK) shares have pulled back about 8% over the past month, prompting some investors to take a closer look at recent performance. The company’s year-to-date return remains positive, and annual revenue and net income have both grown.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/software/nasdaq-adsk/autodesk\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Autodesk.</a></p> <p>Autodesk’s momentum has faded a bit after its recent pullback, but when you zoom out, the picture is still reasonably solid. The 1-year total shareholder return sits at 2.86%, while the three-year total return of 49% shows that long-term holders have been rewarded. Despite some short-term volatility, the company continues to post healthy growth, and the current price may reflect some shifting sentiment or caution about the pace of future gains.</p> <p>If you’re watching the tech space for the next big opportunity, now’s an ideal time to discover <a class=\"company-report-links\" data-vars-link-type=\"cta_tech_and_ai_screener\" href=\"https://simplywall.st/discover/investing-ideas/215171/high-growth-tech-and-ai-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">See the full list for free.</a></p> <p>But does this recent dip signal a chance to pick up Autodesk at a relative bargain, or is the current stock price already accounting for the company’s future growth prospects?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad\" data-cy-id=\"article-body-ad\" data-theme=\"light\" id=\"sws-ad-slot\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><ins class=\"adsbygoogle\" data-ad-client=\"ca-pub-2390341812853401\" data-ad-format=\"fluid\" data-ad-slot=\"4932112108\" data-full-width-responsive=\"false\" style=\"display:block;text-align:center;width:100%;height:100%\"></ins></div></div><h2>Most Popular Narrative: 18.3% Undervalued</h2> <p>Comparing the narrative fair value of $363.71 with the last closing price of $297.08, analysts see significant upside if their projections hold. The narrative combines recent financial momentum with ambitious forecasts for earnings and margin expansion, highlighting factors they believe the market may be underestimating.</p> <blockquote> <p><em>Continued innovation and integration of AI-driven tools (e.g., generative design, AutoConstrain) and industry-specific foundation models are boosting customer productivity and differentiating Autodesk's offerings, supporting premium pricing and driving margin expansion and long-term earnings growth.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/3vnvpju9-analysts-raise-price-targets-on-autodesk-following-strong-results-and-improved-margin-guidance\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Want to know the real engine behind this high valuation? The narrative is built on bold profit growth, climbing margins, and a future multiple that often signals tech outperformance. Which assumptions are shaping this eye-catching target? Click through to uncover the critical numbers that could change how you view Autodesk.</p> <p><strong>Result: Fair Value of $363.71 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/3vnvpju9-analysts-raise-price-targets-on-autodesk-following-strong-results-and-improved-margin-guidance\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, rising competition from open-source platforms and slower customer adoption of new models could challenge Autodesk's growth narrative in the future.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/software/nasdaq-adsk/autodesk\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Autodesk narrative.</a></p> <h2>Another View: Multiples Point to a Different Story</h2> <p>While analysts see Autodesk as undervalued based on future earnings projections, looking at the price-to-earnings ratio tells a contrasting tale. Autodesk is currently trading at 60.6 times earnings, which is much higher than both the US Software industry average of 34.8x and the fair ratio of 42.6x. This suggests that, at today's prices, investors are paying a sizable premium compared to both its peers and what the market might eventually settle on. Could this premium be justified by future outperformance, or is there valuation risk ahead?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/software/nasdaq-adsk/autodesk/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price — find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/software/nasdaq-adsk/autodesk/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:ADSK PE Ratio as at Oct 2025\" class=\"sc-8e1a88f-0 jKVhTH\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/80c3528b-0fb7-4b4b-8e53-c8e1346529d8/chart/pe-multiple-vs-industry\" width=\"746\"/></a><figcaption>NasdaqGS:ADSK PE Ratio as at Oct 2025</figcaption></figure><p> </p><h2> Build Your Own Autodesk Narrative</h2> <p>If you’re the kind of investor who likes to dig into the details and trust your own judgment, it’s easy to craft a narrative tailored to your outlook. <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative\" href=\"https://support.simplywall.st/hc/en-us/articles/10353275550479-Stock-Valuator-with-Narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Do it your way</a>.</p> <p>A great starting point for your Autodesk research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/software/nasdaq-adsk/autodesk\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 1 important warning sign</a> that could impact your investment decision.</p> <h2>Looking for More Winning Stock Ideas?</h2> <p>Take charge of your portfolio by finding unique opportunities others miss. Simply Wall Street's powerful screener uncovers fresh stocks aligned with your goals, so you never settle for ordinary choices.</p> <ul> <li>Unlock stable income potential by tapping into <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/146/dividend-powerhouses-3-yield/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 21 dividend stocks with yields &gt; 3%</a> that offer yields above 3% while maintaining financial strength.</li> <li>Accelerate your growth by targeting <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_ai_stocks\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 26 AI penny stocks</a> poised for success with innovation in artificial intelligence and automation across industries.</li> <li>Catch the next wave of value by uncovering <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/168/undervalued-stocks-based-on-cash-flows/global\" rel=\"noopener noreferrer\" target=\"_blank\">these 856 undervalued stocks based on cash flows</a> with strong fundamentals whose price has yet to reflect their long-term potential.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p></div>",
            "pub_date": "2025-10-31 08:25:47",
            "link": "https://simplywall.st/stocks/us/software/nasdaq-adsk/autodesk/news/a-fresh-look-at-autodesk-adsk-valuation-after-recent-share-p-1",
            "image": "https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        }
    ]
}